Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

Marina Cavazzana-Calvo, Emmanuel Payen, Olivier Negre, Gary Wang, Kathleen Hehir, Floriane Fusil, Julian Down, Maria Denaro, Troy Brady, Karen Westerman, Resy Cavallesco, Beatrix Gillet-Legrand, Laure Caccavelli, Riccardo Sgarra, Leila Maouche-Chrétien, Françoise Bernaudin, Robert Girot, Ronald Dorazio, Geert Jan Mulder, Axel Polack & 18 others Arthur Bank, Jean Soulier, Jérôme Larghero, Nabil Kabbara, Bruno Dalle, Bernard Gourmel, Gérard Socie, Stany Chrétien, Nathalie Cartier, Patrick Aubourg, Alain Fischer, Kenneth Cornetta, Frédéric Galacteros, Yves Beuzard, Eliane Gluckman, Frederick Bushman, Salima Hacein-Bey-Abina, Philippe Leboulch

Research output: Contribution to journalArticle

764 Citations (Scopus)

Abstract

The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound β E0 -thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The β E -globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated β E -globin with partial instability. When this is compounded with a non-functional β 0 allele, a profound decrease in β-globin synthesis results, and approximately half of β E0 -thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe β E0 -thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21months. Blood haemoglobin is maintained between 9 and 10gdl 1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-biased cell clone, in which the integrated vector causes transcriptional activation of HMGA2 in erythroid cells with further increased expression of a truncated HMGA2 mRNA insensitive to degradation by let-7 microRNAs. The clonal dominance that accompanies therapeutic efficacy may be coincidental and stochastic or result from a hitherto benign cell expansion caused by dysregulation of the HMGA2 gene in stem/progenitor cells.

Original languageEnglish (US)
Pages (from-to)318-322
Number of pages5
JournalNature
Volume467
Issue number7313
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Thalassemia
Globins
Genetic Therapy
Hemoglobins
Stem Cells
Alleles
Patient Transfer
Hemoglobinopathies
Messenger RNA
Erythroid Cells
Hematopoietic Stem Cell Transplantation
Alternative Splicing
Graft vs Host Disease
Myeloid Cells
HLA Antigens
Hematopoietic Stem Cells
MicroRNAs
Point Mutation
Transcriptional Activation
Genes

ASJC Scopus subject areas

  • General
  • Medicine(all)

Cite this

Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., ... Leboulch, P. (2010). Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 467(7313), 318-322. https://doi.org/10.1038/nature09328

Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. / Cavazzana-Calvo, Marina; Payen, Emmanuel; Negre, Olivier; Wang, Gary; Hehir, Kathleen; Fusil, Floriane; Down, Julian; Denaro, Maria; Brady, Troy; Westerman, Karen; Cavallesco, Resy; Gillet-Legrand, Beatrix; Caccavelli, Laure; Sgarra, Riccardo; Maouche-Chrétien, Leila; Bernaudin, Françoise; Girot, Robert; Dorazio, Ronald; Mulder, Geert Jan; Polack, Axel; Bank, Arthur; Soulier, Jean; Larghero, Jérôme; Kabbara, Nabil; Dalle, Bruno; Gourmel, Bernard; Socie, Gérard; Chrétien, Stany; Cartier, Nathalie; Aubourg, Patrick; Fischer, Alain; Cornetta, Kenneth; Galacteros, Frédéric; Beuzard, Yves; Gluckman, Eliane; Bushman, Frederick; Hacein-Bey-Abina, Salima; Leboulch, Philippe.

In: Nature, Vol. 467, No. 7313, 2010, p. 318-322.

Research output: Contribution to journalArticle

Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F, Down, J, Denaro, M, Brady, T, Westerman, K, Cavallesco, R, Gillet-Legrand, B, Caccavelli, L, Sgarra, R, Maouche-Chrétien, L, Bernaudin, F, Girot, R, Dorazio, R, Mulder, GJ, Polack, A, Bank, A, Soulier, J, Larghero, J, Kabbara, N, Dalle, B, Gourmel, B, Socie, G, Chrétien, S, Cartier, N, Aubourg, P, Fischer, A, Cornetta, K, Galacteros, F, Beuzard, Y, Gluckman, E, Bushman, F, Hacein-Bey-Abina, S & Leboulch, P 2010, 'Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia', Nature, vol. 467, no. 7313, pp. 318-322. https://doi.org/10.1038/nature09328
Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010;467(7313):318-322. https://doi.org/10.1038/nature09328
Cavazzana-Calvo, Marina ; Payen, Emmanuel ; Negre, Olivier ; Wang, Gary ; Hehir, Kathleen ; Fusil, Floriane ; Down, Julian ; Denaro, Maria ; Brady, Troy ; Westerman, Karen ; Cavallesco, Resy ; Gillet-Legrand, Beatrix ; Caccavelli, Laure ; Sgarra, Riccardo ; Maouche-Chrétien, Leila ; Bernaudin, Françoise ; Girot, Robert ; Dorazio, Ronald ; Mulder, Geert Jan ; Polack, Axel ; Bank, Arthur ; Soulier, Jean ; Larghero, Jérôme ; Kabbara, Nabil ; Dalle, Bruno ; Gourmel, Bernard ; Socie, Gérard ; Chrétien, Stany ; Cartier, Nathalie ; Aubourg, Patrick ; Fischer, Alain ; Cornetta, Kenneth ; Galacteros, Frédéric ; Beuzard, Yves ; Gluckman, Eliane ; Bushman, Frederick ; Hacein-Bey-Abina, Salima ; Leboulch, Philippe. / Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. In: Nature. 2010 ; Vol. 467, No. 7313. pp. 318-322.
@article{e075ed96f455435aa3ea6389151a19cc,
title = "Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia",
abstract = "The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound β E /β 0 -thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The β E -globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated β E -globin with partial instability. When this is compounded with a non-functional β 0 allele, a profound decrease in β-globin synthesis results, and approximately half of β E /β 0 -thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe β E /β 0 -thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21months. Blood haemoglobin is maintained between 9 and 10gdl 1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-biased cell clone, in which the integrated vector causes transcriptional activation of HMGA2 in erythroid cells with further increased expression of a truncated HMGA2 mRNA insensitive to degradation by let-7 microRNAs. The clonal dominance that accompanies therapeutic efficacy may be coincidental and stochastic or result from a hitherto benign cell expansion caused by dysregulation of the HMGA2 gene in stem/progenitor cells.",
author = "Marina Cavazzana-Calvo and Emmanuel Payen and Olivier Negre and Gary Wang and Kathleen Hehir and Floriane Fusil and Julian Down and Maria Denaro and Troy Brady and Karen Westerman and Resy Cavallesco and Beatrix Gillet-Legrand and Laure Caccavelli and Riccardo Sgarra and Leila Maouche-Chr{\'e}tien and Fran{\cc}oise Bernaudin and Robert Girot and Ronald Dorazio and Mulder, {Geert Jan} and Axel Polack and Arthur Bank and Jean Soulier and J{\'e}r{\^o}me Larghero and Nabil Kabbara and Bruno Dalle and Bernard Gourmel and G{\'e}rard Socie and Stany Chr{\'e}tien and Nathalie Cartier and Patrick Aubourg and Alain Fischer and Kenneth Cornetta and Fr{\'e}d{\'e}ric Galacteros and Yves Beuzard and Eliane Gluckman and Frederick Bushman and Salima Hacein-Bey-Abina and Philippe Leboulch",
year = "2010",
doi = "10.1038/nature09328",
language = "English (US)",
volume = "467",
pages = "318--322",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7313",

}

TY - JOUR

T1 - Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

AU - Cavazzana-Calvo, Marina

AU - Payen, Emmanuel

AU - Negre, Olivier

AU - Wang, Gary

AU - Hehir, Kathleen

AU - Fusil, Floriane

AU - Down, Julian

AU - Denaro, Maria

AU - Brady, Troy

AU - Westerman, Karen

AU - Cavallesco, Resy

AU - Gillet-Legrand, Beatrix

AU - Caccavelli, Laure

AU - Sgarra, Riccardo

AU - Maouche-Chrétien, Leila

AU - Bernaudin, Françoise

AU - Girot, Robert

AU - Dorazio, Ronald

AU - Mulder, Geert Jan

AU - Polack, Axel

AU - Bank, Arthur

AU - Soulier, Jean

AU - Larghero, Jérôme

AU - Kabbara, Nabil

AU - Dalle, Bruno

AU - Gourmel, Bernard

AU - Socie, Gérard

AU - Chrétien, Stany

AU - Cartier, Nathalie

AU - Aubourg, Patrick

AU - Fischer, Alain

AU - Cornetta, Kenneth

AU - Galacteros, Frédéric

AU - Beuzard, Yves

AU - Gluckman, Eliane

AU - Bushman, Frederick

AU - Hacein-Bey-Abina, Salima

AU - Leboulch, Philippe

PY - 2010

Y1 - 2010

N2 - The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound β E /β 0 -thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The β E -globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated β E -globin with partial instability. When this is compounded with a non-functional β 0 allele, a profound decrease in β-globin synthesis results, and approximately half of β E /β 0 -thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe β E /β 0 -thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21months. Blood haemoglobin is maintained between 9 and 10gdl 1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-biased cell clone, in which the integrated vector causes transcriptional activation of HMGA2 in erythroid cells with further increased expression of a truncated HMGA2 mRNA insensitive to degradation by let-7 microRNAs. The clonal dominance that accompanies therapeutic efficacy may be coincidental and stochastic or result from a hitherto benign cell expansion caused by dysregulation of the HMGA2 gene in stem/progenitor cells.

AB - The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound β E /β 0 -thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The β E -globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated β E -globin with partial instability. When this is compounded with a non-functional β 0 allele, a profound decrease in β-globin synthesis results, and approximately half of β E /β 0 -thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe β E /β 0 -thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21months. Blood haemoglobin is maintained between 9 and 10gdl 1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-biased cell clone, in which the integrated vector causes transcriptional activation of HMGA2 in erythroid cells with further increased expression of a truncated HMGA2 mRNA insensitive to degradation by let-7 microRNAs. The clonal dominance that accompanies therapeutic efficacy may be coincidental and stochastic or result from a hitherto benign cell expansion caused by dysregulation of the HMGA2 gene in stem/progenitor cells.

UR - http://www.scopus.com/inward/record.url?scp=77956928344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956928344&partnerID=8YFLogxK

U2 - 10.1038/nature09328

DO - 10.1038/nature09328

M3 - Article

VL - 467

SP - 318

EP - 322

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7313

ER -